Trial Profile
A retrospective real-world study evaluating efficacy and safety of Ixazomib in combination with Lenalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology